netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Introduction

Preferred Prescribing list for North Staffordshire CCGs, including University Hospitals of North Midlands NHS Trust, Midlands Partnership NHS Foundation Trust and North Staffordshire Combined Healthcare NHS Trust

Useful Links

ESCAs Guidelines and Clinical Pathways Patient Group Directions
Formulary Documentation High Cost Drugs Information Drug Discontinuations & Shortages
Area Prescribing Committee Documents New Medicines Committee Documents Monthly Newsletters
Self Care and Over the Counter Medicines Prescribing Decline To Prescribe Form  Care Home Prescribing Resourses
Covid 19 - Interim Clinical Information    

 CCG Formularies

South Staffordshire Joint Formulary  Central & Eastern Cheshire Formulary  Birmingham & Surrounds Formulary

Clinical Formularies

Woundcare Formulary Continence Prescribing Formulary Antimicrobial Guidelines
How to guide for North Staffordshire Joint Formulary  

 

News Feed

10/12/2020: New ESCAs in North Staffordshire

Two ESCAs were approved by the Area Prescribing Committee (North) in September 2020 for use in North Staffordshire. They are:

  • Methotrexate for the treatment of Autoimmune Rheumatic diseases (Version 4.1)- This was updated to include additional monitoring information if prescribed concurrently with Leflunomide.
  • Tizanidine for the treatment of spasticity associated with brain injuries, multiple sclerosis or spinal cord injury or disease (Version 1.0)- This is a new ESCA developed by MPFT.

Note that both drugs have an ‘Amber-E’ status on the North Staffs formulary for the relevant indications, thus transfer of prescribing into primary care MUST be accompanied by an agreed ESCA form.

All APC approved ESCAs are available on netFormulary via the link: http://www.northstaffordshirejointformulary.nhs.uk/docs/esca/

For any prescribing-related issues, please contact the respective medicines optimisation team.


3/11/2020 PRODUCT DISCONTINUATION:

Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen (exenatide once-weekly) will be discontinued from 31/12/2020. Clinicians should note that the old device is being replaced by the Bydureon BCise pen (exenatide 2mg prolonged-release injectable suspension); a once weekly, single use, fixed dose pen with a hidden needle that automatically injects the required dose, allowing for simpler administration compared to the old Bydureon device. Prior to prescribing and administration of this new device, patient and caregivers training must be undertaken by a healthcare professional


7/10/20 Smoking Cessation Information Update

Everyone Health, the service provider for smoking cessation service confirms it is now open to all tobacco smokers, living anywhere in Staffordshire, aged 40 years and over. Referrals can still be made by calling the contact centre on 0333 005 0095, or via email: eh.staffs@nhs.net


4/8/20 Updated Gluten-Free Prescribing policy 2020

The updated Gluten-Free Prescribing policy 2020 can be found on the Homepage, Guidelines and Clinical Pathways link on the North Staffordshire Joint Formulary.


24/7/2020 - Updated Rheumatology ESCA’s

Midlands Partnership NHS Foundation Trust (MPFT) have updated their contact details for their Rheumatology ESCA’s to reflect their dedicated email address: haywoodrheumatology@esca.nhs.net

The updated documents can be found on the ESCA’s link on the North Staffordshire Joint Formulary Home page.


07/05/2020 - New Covid-19 information link

The North Staffordshire Joint Formulary has a new COVID 19 link titled Interim Clinical Information. Please use this link to access local and national documents recommending advice and guidance during this time. If you have any queries relating to this please use the Feedback tab on the formulary front page.

Medicines Information Team


>>> more news

 

 


NetFormulary
   Last updated: 26/01/2021 15:31:41..